From October 1, 2022 to December 31, 2022, the company has repurchased 0 shares, representing 0% for ?0 million. With this, the company has completed the repurchase of 2,052,808 shares, representing 3.72% for ?135.01 million under the buyback announced on November 3, 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
85.68 EUR | -0.78% |
|
-0.18% | +41.61% |
26/06 | Rovi receives non-binding offers for manufacturing business | RE |
08/05 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.78% | 4.8B | |
+55.55% | 816B | |
+40.44% | 634B | |
-6.83% | 351B | |
+17.15% | 323B | |
+7.09% | 293B | |
+14.04% | 238B | |
+1.43% | 222B | |
+13.47% | 218B | |
+7.87% | 167B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.